Antitope Announces Research Agreement with Fraunhofer Institute for Cell Therapy and Immunology
Antitope Ltd., a leader in antibody and protein engineering, today announced a research agreement with Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI). Under the Agreement, Antitope will engineer a novel antibody developed by Fraunhofer IZI to produce an improved therapy for the treatment of transplantation patients.
"We are delighted to be working with a world class biomedical research organization such as the Fraunhofer Institute for Cell Therapy and Immunology" said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "We look forward to an excellent and productive partnership and, in particular, the successful development of a treatment to help reduce the incidence of rejection during transplantation."
Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins through humanization and de-immunisation technologies. Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit: